| Literature DB >> 24980409 |
Jan van der Greef1, Aram Adourian2, Pieter Muntendam3, Robert N McBurney2.
Abstract
Too few drug discovery projects generate a marketed drug product, often because preclinical studies fail to predict the clinical experience with a drug candidate. Improving the success of preclinical-to-clinical translation is of paramount importance in optimizing the pharmaceutical value chain. Here, we advance the case for a molecular systems approach to crossing the preclinical-to-clinical translational chasm and for metabolomic analysis of readily accessible bodyfluids as a key technology in translational activities.: � 2006 Published by Elsevier Ltd.Year: 2006 PMID: 24980409 DOI: 10.1016/j.ddtec.2006.05.003
Source DB: PubMed Journal: Drug Discov Today Technol ISSN: 1740-6749